Catalyst Dossier · compiled by CeliA 🧫
ORAMED PHARMACEUTICALS INC. (ORMP)
Pharmaceutical Preparations · market cap $159M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
9
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Oramed Pharmaceuticals (ORMP) is a Jerusalem-based clinical-stage biotech focused on oral drug delivery systems, most notably oral insulin capsules for diabetes and NASH. The company's lead asset ORMD-0801 remains in Phase 2 across multiple indications including Type 1 and Type 2 diabetes and NASH, with no Phase 3 programs disclosed. At a $165M market cap and only $13.2M in cash — roughly 13.6 months of runway — the company faces acute financing pressure ahead of any meaningful data readout.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ORMD-0801 QD | Phase 2 | Nonalcoholic Steatohepatitis (NASH) |
| ORMD-0801 (qd) | Phase 2 | Type 2 Diabetes Mellitus |
| ORMD-0801 Dose # 1 | Phase 2 | Diabetes Mellitus Type 2 |
| ORMD-0801 | Phase 2 | Diabetes Type 2 |
| ORMD-0801 Capsules | Phase 2 | Diabetes Mellitus Type 1 |
| ORMD-0801 Treatment A | Phase 2 | Type 1 Diabetes |
| ORMD-0801 (Insulin) capsule 8 mg BD | Phase 2 | Diabetes Mellitus, Type 2 |
| Oral Insulin | Phase 2 | Non-Alcoholic Steatohepatitis (NASH) |
| Cohort A: ORMD-0801 | Phase 2 | T2DM (Type 2 Diabetes Mellitus) |
Price & technical context
3-month
-8.0%
6-month
+23.9%
12-month
+103.3%
52-wk range
$2.06–$5.00
vs 50-day MA
+3.2%
vs 200-day MA
+21.0%
Realized vol
53.5%
Max drawdown
-24.0%
Daily closes through 2026-08-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ORMP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.